Results 181 to 190 of about 38,200 (304)

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source

A Cohort Study on Incidence and Factors Associated With Adverse Drug Reactions of Enalapril in Lusaka, Zambia

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Angiotensin‐converting enzyme inhibitors (ACEIs) are widely prescribed but are associated with adverse drug reactions (ADR), including angioedema, which is typically reported in 0.1%–0.7%. Data from sub‐Saharan Africa are limited. This study aimed to estimate the incidence and risk factors of enalapril‐associated ADRs in a Zambian cohort, with
Ntemena Yikon'a, Ngosa Mumba, Sarah Pedretti, Helen Hoenck, Jonathan Peter, Owen Ngalamika   +5 more
wiley   +1 more source

Genomic Medicine Sweden: Advancing precision medicine at the national level

Journal of Internal Medicine, Volume 300, Issue 4, Page 397-419, October 2026.
Abstract High‐throughput sequencing has transformed clinical diagnostics of rare diseases (RD), cancer and infectious diseases by enabling the identification of disease‐causing genetic alterations and facilitating individualised treatment and care.
Anders Edsjö, Anna Lindstrand, Panagiotis Baliakas, David Gisselsson, Paula Mölling, Mia Wadelius, Åsa Johansson, Hannes Olauson, Hans Ehrencrona, Lovisa Lovmar, Christian G. Giske, Henrik Green, Ann Nordgren, Fulya Taylan, Martin Hallbeck, Erika Tång Hallbäck, Anna Green, Markus Heidenblad, Kina Höglund, Anders Jemt, Carl Mårten Lindqvist, Maria Johansson Soller, Magnus Sabel, Colum Walsh, Hartmut Vogt, Craig E. Wheelock, Martin Bergö, Jens Enoksson, Ann Ekberg Jansson, Cecilia Fagerström, Jan Holgersson, Stephanie Anja Juran, Mats G. Karlsson, Frida Lundmark, Eva Tiensuu Janson, Andreas Muranyi Scheutz, Malin Sund, Päivi Östling, Sofia Gruvberger‐Saal, Marene Landström, Malin Melin, Lars Palmqvist, Richard Palmqvist, Bianca Stenmark, Anna Wedell, Malin Karnå, Katarina Nyström, Tobias Strid, Per Sikora, Maria Johansson, Therese Fagerqvist, Mirja Carlsson Möller, Oskar Frisell, Mats Ulfendahl, Mikaela Friedman, Lucia Cavelier, Valtteri Wirta, Thoas Fioretos, Richard Rosenquist   +58 more
wiley   +1 more source

Science of omics: a molecular space odyssey

Experimental Physiology, EarlyView.
Salomé Coppens, Christophe Hirtz, Margaux Vignon, Damian M. Bailey   +3 more
wiley   +1 more source

Prevalence of 21 Physician‐Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier, Brittany Grantham, Camilla Grud Nielsen, Louise Lundgren, Liv Andrés‐Jensen, Kjeld Schmiegelow, Chris Selman, Gareth Ball, Elyse Passmore, David A. Elliott, Rachel Conyers   +10 more
wiley   +1 more source

The Role of Pharmacogenomics Studies for Precision Medicine Among Ethiopian Patients and Their Clinical Implications: A Scoping Review [PDF]

Kefyalew Ayalew Getahun,1 Dessie Abebaw Angaw,2 Mezgebu Silamsaw Asres,3 Wubayehu Kahaliw,1 Zelalem Petros,4 Solomon Mequanente Abay,4 Getnet Yimer,5 Nega Berhane6 1Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences ...
Petros Z, Kahaliw W, Yimer G, Angaw DA, Berhane N, Asres MS, Getahun KA, Abay SM   +7 more
core  

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3115-3123, September 2026.
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong, Jungryul Kim, Woojin Jung, Jiyeon Jeon, Hyeongjun Jo, Kyoung‐Bin Ryu, Ja‐Young Hong, Kwan Soo Kim, Seongjun Yang, Hee Young Ju, Hwi‐yeol Yun, Jung‐woo Chae, Keon Hee Yoo, Soyoung Lee   +13 more
wiley   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3246-3256, September 2026.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3257-3264, September 2026.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source